Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Isunakinra - Buzzard Pharmaceuticals

Next Previous
Drug Profile

Isunakinra - Buzzard Pharmaceuticals

Alternative Names: EBI 005 1; EBI 005 2; EBI-005

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eleven Biotherapeutics
  • Developer Buzzard Pharmaceuticals; Eleven Biotherapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Immunotherapies; Peptides; Proteins; Recombinant proteins
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma
  • Phase I/II Solid tumours
  • Discontinued Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 30 Jan 2025 Phase-II clinical trials in Adenocarcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT06634875, BUZ02CD101)
  • 30 Jan 2025 Phase-II clinical trials in Adenocarcinoma (Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease, Metastatic disease, Monotherapy) in USA (unspecified route) (NCT06634875, BUZ02CD101)
  • 15 Oct 2024 Buzzard Pharmaceuticals plans a phase II trial in Adenocarcinoma (Metastatic disease, Combination therapy, Late-stage disease, Unresectable/Inoperable, Second-line therapy or greater) in USA in December 2024 (NCT06634875)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top